Ezek Mathew

Mr. Ezek Mathew

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 March 2022 in Cerebral Circulation - Cognition and Behavior
Verified
Journal Article
Open access
RVRaul Vintimilla
Raul Vintimilla
EMEzek Mathew
Ezek Mathew
JHJames Richard Hall
James Richard Hall
LJLeigh Johnson
Leigh Johnson
SOSid O'bryant
Sid O'bryant
Subjective cognitive complaints (SCC) are associated with higher risk of mild cognitive impairment (MCI) and dementia. Cardiovascular risk factors (CVRF) have been also associated with cognitive decline, MCI, and dementia. Few studies have examined the associated of CVRF and SCC. Participants were cognitively normal Mexican Americans from the HABLE study. Participants were categorized as with and without SCC, and SCC was also measured as a continuous variable. CVRF diagnosis were ascertained during consensus review. Cognitive measures used were MMSE, Trails B, SEVLT, and digit span. Logistic regression and linear regression were used to asses the association of SCC with CVRF and cognitive scores. A total of 673 participants [mean age 63.3 (SD=7.71), 69.2% female] were included. SCC was present in 323 participants (47.99%). Dyslipidemia and depression were associated with SCC. Individuals with dyslipidemia had 1.72 times the odds (95% CI = 1.20 to 2.47) of SCC, and those with depression had 3.15 times the odds (95% CI = 2.16 to 4.59) of self-reporting SCC. Higher SCC scores, were significantly associated with MMSE (B = 0.07; SE = 0.03; p = 0.02), and SEVLT immediate and delayed (B= -0.03; SE = 0.00; p = 0.000 and B = -0.03; SE = 0.00; p = 0.000, respectively). In a cognitively normal Mexican Americans sample of older adults, depression and dyslipidemia were correlated with self-reported SCC. A greater self-perception of cognitive decline correlated with lower scores on the MMSE and SEVLT.

12 December 2022 in Journal of Neurosurgery: Case Lessons
Verified
Journal Article
Open access
PDF file
EMEzek Mathew
Ezek Mathew
JWJulie Williamson
Julie Williamson
LMLois Mamo
Lois Mamo
RDRob Dickerman
Rob Dickerman
BACKGROUND: Transverse myelitis is a rare neurological occurrence with varied presentation. Imaging is necessary to properly diagnose this condition; however, identifying the cause of this condition may often be difficult. OBSERVATIONS: An otherwise healthy patient presented to the clinic with peculiar neurological symptoms without an obvious underlying cause. Imaging evidenced no significant structural defects but did lead to discovery of cord enhancement compatible with a diagnosis of transverse myelitis. Corticosteroid treatment was initiated rapidly to address this pathology, and the patient recovered without deficits. To identify the underlying cause, patient medical history was reviewed thoroughly and compared with existing literature. Previous tuberculosis infection could be a less likely cause of the neurological symptoms. However, recent vaccination with the Johnson & Johnson coronavirus disease 2019 (COVID-19) vaccine could be a more likely cause of the transverse myelitis, which has been rarely reported. LESSONS: Transverse myelitis after COVID-19 infection has been an escalating phenomenon. However, transverse myelitis after COVID-19 vaccination is a rare occurrence that is also on the rise. Given the increased rates of vaccination, transverse myelitis should not be overlooked as a potential pathology, due to the severity of neurological impairment if this condition is not treated rapidly.

21 July 2025 in ACS Omega
Verified
Journal Article
Open access
EMEzek Mathew
Ezek Mathew
KEKyle A. Emmitte
Kyle A. Emmitte
JLJin Liu
Jin Liu
Designing selective and potent ligands for target receptors remains a significant challenge in drug discovery. Computational approaches, particularly advancements in machine learning (ML), offer transformative potential in addressing this challenge. In this study, our goal was to develop a composite ML model capable of predicting ligand selectivity and potency with high accuracy while also providing interpretable insights to guide ligand optimization. To achieve this goal, we first compiled a data set of 757 ligands, including metabotropic glutamate receptor subtype 2 (mGlu2) negative allosteric modulators (NAMs), metabotropic glutamate receptor subtype 3 (mGlu3) NAMs, and nonselective dual mGlu2/3 NAMs from patent filings. In three phases, we developed an ML model with Interpretable Graph Attention (I-GAT) networks for drug optimization. In phase 1, we created a composite model that can accurately predict selectivity and potency metrics by integrating graph architecture with transfer learning methodologies. Our model demonstrated over 97% accuracy in predicting ligand NAM selectivity and upward of 78% accuracy in potency prediction. Phase 2 used attention mechanisms to enhance model interpretability, effectively illuminating the “black box” of ML decision-making. Finally, in phase 3, we utilized attention gradients to intelligently modify known ligands, leading to the design of a novel ligand with predicted superior properties compared to the original. Our approach demonstrates the dual benefits of predictive accuracy and atom-level interpretability, offering a powerful framework for ligand design. When applied to external data, our model matched and, in some cases, exceeded the performance of current state-of-the-art chemistry-focused ML models across multiple data sets. Ultimately, our model has the potential to be adapted to other receptors and molecular properties, paving the way for a more efficient and targeted drug discovery process.

6 December 2025 in Cancers
Verified
Journal Article
Open access
PDF file
LCLuke C. Cooksey
Luke C. Cooksey
THTamara Hoteit
Tamara Hoteit
EMEzek Mathew
Ezek Mathew
NSNirupama Sabnis
Nirupama Sabnis
RDRob Dickerman
Rob Dickerman
PMPorunelloor A. Mathew
Porunelloor A. Mathew
Background/Objectives: Glioblastoma (GBM) is a lethal form of primary brain tumor. There has been minimal improvement in overall GBM survival in recent years. To increase survival in patients with GBM, it is important to study novel GBM molecular antigens to form the basis of better diagnostics, prognostic measures, and therapeutic advancements. Our goal is to find more robust GBM-specific antigenic biomarkers to eventually improve GBM outcomes. Here, we initiated an investigation into cell-surface PCNA (csPCNA), a potential GBM biomarker and antigenic target. Methods: We utilized flow cytometry, imaging flow cytometry, and cell-surface Western blot to identify the expression of csPCNA on GBM cell lines (LN-229, LN-18) and a primary patient-derived tumor specimen. We then employed flow cytometry to study the associative co-expression of csPCNA with other biomarkers of GBM stem cells (CD44, CD49f) and GBM immunosuppression (PD-L1, TGFβRII). Results: We elucidated that LN-229, LN-18, and the primary GBM patient cells express csPCNA. We found that csPCNA is co-expressed with CD44, CD49f, PD-L1, and TGFβRII on the primary patient-derived GBM specimen. Conclusions: Our findings that csPCNA is expressed in GBM and is co-expressed with stem cell and immunosuppressive biomarkers indicate that csPCNA may be a potentially useful clinical–pathological biomarker for GBM stemness and immunosuppression.

28 November 2025 in Radiation
Verified
Journal Article
Open access
PDF file
EMEzek Mathew
Ezek Mathew
RMReyhan Meetheen
Reyhan Meetheen
ASAnand Shivnani
Anand Shivnani
RDRob Dickerman
Rob Dickerman
Radiation therapy (RT) has been one of the standard treatments for prostate cancer; however, its potential impact on nearby neural structures, such as the lumbosacral plexus (LSP), is often overlooked. The lack of contouring in treatment plans has led to unintended consequences. Radiation-induced lumbosacral plexopathy (RILSP) is a rare but serious complication that presents with progressive lower extremity sensory changes and weakness, mimicking radiculopathy. We report the case of a 66-year-old male who developed bilateral lower extremity neurological deficits post-pelvic radiation for prostate cancer. Radiographically, no compressive lesions were found, and the Electromyography (EMG) revealed involvement of nerves inconsistent with radiculopathy. This led to the diagnosis of RILSP. This case highlights the importance of recognition of RILSP in contrast to radiculopathy in patients with unexplained neurological symptoms after pelvic RT. This highlights the importance of incorporating the LSP as an organ at risk while planning for RT and reviewing retrospectively the dosimetry. It also emphasizes the need for improved contouring of LSP in radiation planning to minimize adverse effects. This sentiment is reflected in the literature, along with the consensus that more research is needed to address the true rate of RILSP.

30 April 2026 in Brain Sciences
Verified
Journal Article
Open access
PDF file
NSNirupama Sabnis
Nirupama Sabnis
LCLuke C. Cooksey
Luke C. Cooksey
HJHareesh Jayakumar
Hareesh Jayakumar
MMMariana Luisa Moguel Mendez
Mariana Luisa Moguel Mendez
EMEzek Mathew
Ezek Mathew
Bruce BunnellBruce Bunnell
Bruce Bunnell
Glioblastoma (GB) remains the most aggressive primary brain malignancy, with the Stupp regimen persisting as the standard of care for nearly two decades despite poor survival outcomes. This review was synthesized by extensively reviewing and analyzing the literature from PubMed, Scopus, and Web of Science to evaluate the emerging promising therapeutic and diagnostic strategies for combating GB. Results indicate significant progress in molecularly targeted therapies, biomimetic nanocarriers, and advanced radiotherapy. While immunotherapeutic approaches, such as checkpoint inhibitors and vaccines, show variable clinical success, the integration of bioinformatics and machine learning has significantly enhanced treatment response prediction. Furthermore, advances in radiomics and molecular imaging have improved the differentiation between true tumor progression and pseudoprogression, potentially reducing invasive diagnostic requirements. Additionally, other emerging and investigational adjuvant therapeutic approaches have shown promise. We conclude that, while multimodal strategies integrating molecular and computational approaches offer a path toward personalized GB management, significant barriers—namely tumor heterogeneity and the blood–brain barrier—persist. Future research must prioritize precision-based combinatorial models to successfully translate these preclinical advancements into improved clinical outcomes for patients.